Clinical Trials

Neurogene Doses First Participant in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome

Taysha Receives FDA Breakthrough Therapy Designation for TSHA-102

Taysha Advances REVEAL Pivotal Trial for Rett Syndrome

Neurogene Announces Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

How Will Cuts to FDA and NIH Impact Gene Therapy Clinical Trials and Rett Syndrome Research?

A Review of Gene Therapy Clinical Trials

Staying Resolute in Challenging Times

With Heavy Hearts

Neurogene Releases Update on NGN-401 Clinical Trial High Dose

Taysha Releases Financial, Enrollment Update and Community Letter

Neurogene Announces Interim Results from Gene Therapy Clinical Trial

Stepping Out of The Dark Ages and Into The Data

Taysha Rett Program Updates Q2 2024

Taysha Announced New Clinical Data from the REVEAL Phase 1/2 Adolescent & Pediatric Trial Evaluating TSHA-102

FDA Selects Neurogene Rett Program for START Pilot Program

Taysha Rett Program Updates March 2024

Neurogene Announces Updates to Pediatric Gene Therapy Clinical Trial

Taysha Provides Updates for all their Clinical Trials (CAN, US, UK)